The Biotech Industry within the last 5 years has seen a significant influx of capital into their firms due to their cutting edge technologies, the mapping of the human genome and a wave of new biologic drug product approvals by the FDA. This influx of capital, which has come from venture capitalists, private investors, off balance sheet financial arrangements, convertible debt instruments, alliance revenue and product sales, has changed the Biotech business model. (Industry Trends, Internal Revenue Service)